X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds will advance the development activities of the Company's assets, with a particular focus on progressing towards the clinical phase, including ExoPTEN, targeted at acute Spinal Cord Injury is being developed using ExoTherapy Technology and Platform.
Lead Product(s): ExoPTEN
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoPTEN
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $2.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement March 27, 2024
Details:
Vivox will provide Contract Research Organization services to NurExone, as a prerequisite to commencing human trials representing a significant step towards filing an IND application in the US for NurExone’s ExoPTEN exosome-based therapy for spinal cord injury.
Lead Product(s): ExoPTEN
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoPTEN
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Vivox
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 22, 2024
Details:
ExoPTEN comprises exosomes loaded with small interfering RNA (siRNA) that inhibits the production of the PTEN protein. It is being evaluated in preclinical studies for the treatment of acute spinal cord injury.
Lead Product(s): ExoPTEN
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoPTEN
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2024
Details:
The collaboration aims at combining Inteligex’s more than twenty years of experience in cell-based therapies and NurExone’s innovative exosome platform to develop therapies for patients with chronic spinal cord injuries.
Lead Product(s): Exosome-based Therapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Inteligex
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2024
Details:
The proceeds will advance the development activities of the Company's assets, with a particular focus on progressing towards the clinical phase, including ExoPTEN, targeted at acute Spinal Cord Injury is being developed using ExoTherapy Technology and Platform.
Lead Product(s): ExoPTEN
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoPTEN
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $1.4 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 05, 2024
Details:
ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI), yielding neuron regeneration and rewiring in traumatically damaged spinal cord.
Lead Product(s): Biologically-guided Exosome Therapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoTherapy
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
NurExone is in the process of developing the ExoPTEN product specifically for acute spinal cord injuries. This collaborative effort opens the possibility for the company to expand its focus to chronic spine injuries by developing Exo Therpies.
Lead Product(s): ExoTherapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Israeli Shekels
Deal Size: $0.2 million Upfront Cash: Undisclosed
Deal Type: Funding October 11, 2023
Details:
ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI), yielding neuron regeneration and rewiring in traumatically damaged spinal cord.
Lead Product(s): Exosome
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoPTEN
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 13, 2023
Details:
ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI), yielding neuron regeneration and rewiring in traumatically damaged spinal cord.
Lead Product(s): Exosome
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoPTEN
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2023
Details:
ExoPTEN is being developed to be a minimally invasive ExoTherapy for spinal cord injuries (SCI), yielding neuron regeneration and rewiring in traumatically damaged spinal cord.
Lead Product(s): Biologically-guided Exosome Therapy
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ExoTherapy
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
